<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883194</url>
  </required_header>
  <id_info>
    <org_study_id>PRF108-POC99-09</org_study_id>
    <nct_id>NCT00883194</nct_id>
  </id_info>
  <brief_title>A Safety and Effectiveness Pilot Study of PRF-108 and PRF-110 in Healthy Volunteers</brief_title>
  <official_title>A Single-center, Randomized, Placebo-controlled, Double-blind, Single-dose, Efficacy of PRF-108 4% and PRF-110 4% Versus Ropivacaine Solution 0.5% in an Experimental Pain Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PainReform LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PainReform LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel&#xD;
      formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers.&#xD;
      PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel&#xD;
      formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers.&#xD;
      PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.&#xD;
&#xD;
      The purpose of this study is to investigate the safety (side effects if any occurs)&#xD;
      associated with the single administration of PRF-108 or PRF-110 and evaluate their analgesic&#xD;
      effect in an experimentally induced pain model compared with ropivacaine Solution 0.5% and&#xD;
      Vehicle Gel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The duration of analgesia</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PRF-108 and PRF-110 Safety</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRF-108 Gel, 4% ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PRF-108 Gel, Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine Solution 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRF-110, 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRF-110, 4% ropivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRF-108</intervention_name>
    <description>Ropivacaine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PRF-108 Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Solution</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRF-110</intervention_name>
    <arm_group_label>PRF-110, 4%</arm_group_label>
    <other_name>ropivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects between 18-60 years of age;&#xD;
&#xD;
          2. Subjects are within Â±10% of ideal body weight/height (based on frame size) as given by&#xD;
             the Metropolitan Life Insurance Tables;&#xD;
&#xD;
          3. Subjects are ASA Category I and in normal physical health as judged by physical and&#xD;
             laboratory examinations and have a negative urine based screen for drugs of abuse;&#xD;
&#xD;
          4. Subjects must agree to refrain from ingesting any analgesic medication for 3 days or 5&#xD;
             half-lives of the drug prior to and during the study period and alcohol for 1 day&#xD;
             prior to and during the study period;&#xD;
&#xD;
          5. Subjects can tolerate a 0.5mL injection of saline in the lower back area.&#xD;
&#xD;
          6. The subject is capable of reading, comprehending, and signing the informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of any significant hepatic, renal, endocrine, cardiac,&#xD;
             neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic&#xD;
             disorders, including glaucoma, diabetes, emphysema, and chronic bronchitis;&#xD;
&#xD;
          2. Subjects with a history of any type of cancer;&#xD;
&#xD;
          3. Subjects with conditions that affect the absorption, metabolism, or passage of drugs&#xD;
             out of the body, (e.g., sprue, celiac disease, Crohn's disease, colitis, or liver,&#xD;
             kidney, or thyroid conditions);&#xD;
&#xD;
          4. Subjects with any history of alcohol or substance abuse (including a positive drug&#xD;
             screen test);&#xD;
&#xD;
          5. Subjects that currently have or have a history of hypertension;&#xD;
&#xD;
          6. Subjects with a known hypersensitivity to any local anesthetic drug;&#xD;
&#xD;
          7. Subjects with a history of benign prostatic hyperplasia or difficulty in urination;&#xD;
&#xD;
          8. Subjects with a hematocrit level below the normal range on the screening laboratory&#xD;
             examination;&#xD;
&#xD;
          9. Subjects with any clinically significant abnormal lab result (as judged by the&#xD;
             Principal Investigator);&#xD;
&#xD;
         10. An abnormal ECG at screening including PR&gt;200 ms, QRS&gt;110 ms, QTcF&lt;380 or &gt;400 ms,&#xD;
             lead II T wave abnormalities. Non-specific T wave abnormalities in leads other than&#xD;
             lead II are permissible if not accompanied by any other morphological abnormalities.&#xD;
&#xD;
         11. Subjects with any condition or history felt by the Investigator to place the subject&#xD;
             at increased risk;&#xD;
&#xD;
         12. Subjects who have smoked or chewed tobacco-containing substances within 6 months prior&#xD;
             to the start of the study;&#xD;
&#xD;
         13. Subjects judged by the Investigator to be unable or unwilling to comply with the&#xD;
             requirements of the protocol;&#xD;
&#xD;
         14. Subjects who have used an investigational drug within 30 days prior to entering the&#xD;
             study;&#xD;
&#xD;
         15. Subjects who have donated blood within 3 months prior to the start of the study&#xD;
             (including blood donation related to the surgical procedure);&#xD;
&#xD;
         16. Subjects who have previously participated in the trial;&#xD;
&#xD;
         17. Subjects who are members of the study site staff directly involved with the study or a&#xD;
             relative of the Sponsor or other personnel involved with the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Naveh</last_name>
    <role>Study Chair</role>
    <affiliation>PainReform LTD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Experimental Pain Model</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

